| Ytd | -32.22% | |
| 1y | 5.69% |
| Open | 4.41 | Prev Close | 4.46 | Low | 4.40 | High | 4.50 | Mkt Cap | 161.91M |
| Vol | 236.05K | Avg Vol | 1.54M | EPS | -1.17 | P/E | -3.81 | Forward P/E | -1.34 |
| Beta | 0.41 | Short Ratio | 1.19 | Inst. Own | 30.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 4.81 | 200-d Avg | 5.51 | 1yr Est | 12.42 |
IMRX News
- Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, includin
Needham analyst Ami Fadia maintains Immuneering (NASDAQ:IMRX) with a Buy and raises the price tar
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage cli
Immuneering (IMRX) might move higher on growing optimism about its earnings prospects, which is refl
- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthen
Immuneering stock rises after dosing the first patient in a pivotal phase III study of atebimetinib
Global pivotal Phase 3 trial will evaluate efficacy and safety of atebimetinib + modified gemcitabin
Immuneering Corporation (IMRX) Discusses Positive Atebimetinib ASCO Data Update in First-Line Pancre
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with A
US stocks rose, Dow gained over 400 points. S&P 500 and NASDAQ also up. Health care shares jumpe
Zoom Communications Inc shares rise after strong financial results and increased buyback authorizat
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer P
- New survival data from Phase 2a clinical trial evaluating atebimetinibmGnP in first-line metastati
Immuneering Corporation (IMRX) presents promising early data in frontline metastatic pancreatic canc
- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic canc
Analysis of circulating tumor DNA from atebimetinib-treated patients shows acquired MAPK pathway alt
Immuneering (NASDAQ: IMRX) CEO Benjamin J. Zeskind told investors at a Needham conference session th
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage cl
Shares of Immuneering Corporation (NASDAQ: IMRX - Get Free Report) have earned a consensus rating of
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients
Oxford BioMedica (OTCMKTS:OXBDF - Get Free Report) and Immuneering (NASDAQ: IMRX - Get Free Report)
Benzinga examined the prospects for many investors' favorite stocks over the last week — here
On Friday, 1043 companies hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.
On Monday, 71 stocks hit new 52-week lows.
On Friday, 209 companies set new 52-week lows.